Español Inglés
Acceso usuarios

Big Data

AI in oncology: solving the sequencing puzzle in a biomarker-driven era

16-06-2025

At the 2025 ASCO Annual Meeting, artificial intelligence (AI) moved from theoretical promise to demonstrated clinical utility. Amid the surge of presentations on precision oncology, one theme became increasingly clear: as the number of actionable biomarkers increases, so does the complexity of sequencing treatments. AI may be the only tool agile enough to keep up. The biomarker pool is expanding rapidly. With tumor profiling now yielding dozens of potentially actionable signals, the sequencing question becomes central: Which target do we prioritize? What’s the optimal order of therapies? And how do we make decisions in the absence of head-to-head trials or long-term data?

Machine Learning-Based Radiomics for Differentiating Lung Cancer Subtypes in Brain Metastases Using CE-T1WI

09-06-2025

The purpose of this research was to create and validate radiomic models based on machine learning that can effectively discriminate between primary non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in individuals with brain metastases (BMs) by utilizing high-dimensional radiomic characteristics derived from contrast-enhanced T1-weighted imaging (CE-T1WI).

Deep learning can predict lung cancer risk from single LDCT scan

03-06-2025

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new research published at the ATS 2025 International Conference, and in American Journal of Respiratory and Critical Care Medicine. The model, called Sybil, which was originally developed using National Lung Screening Trial (NLST) data by investigators from the Massachusetts Institute of Technology and Harvard Medical School, could be used to guide more personalized lung cancer screening strategies.

AI algorithm created to predict response to immunotherapy in lung cancer

19-05-2025

María Jesús Ledesma, a researcher at UPM and CIBER-BBN, has developed an artificial intelligence algorithm capable of predicting which lung cancer patients will respond to immunotherapy. The tool is powered by real-world clinical data and routine blood tests, allowing it to predict treatment effectiveness and reduce adverse effects. The trailer, published in Cancer Immunology, Immunotherapy, represents a key step toward more accessible personalized medicine. The project was carried out in collaboration with leading hospitals and biomedical research centers in Spain.

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity

12-05-2025

Overdiagnosis in cancer care remains a significant concern, often resulting in unnecessary physical, emotional, and financial burdens on patients. Artificial intelligence (AI) has the potential to address this challenge by enabling more accurate, personalized cancer diagnoses and facilitating tailored treatment plans. Integrating AI with precision medicine can minimize unnecessary treatments and associated adverse effects by optimizing care strategies based on individual patient data. However, the integration of AI in oncology requires rigorous research and validation to ensure its effectiveness across diverse populations and clinical settings.

Acceso al ‘Big Data’ sanitario para acelerar la investigación en cáncer

05-05-2025

Según el Informe de EIT Health, aunque existen diferencias regionales, el sistema sanitario español en general ha alcanzado un alto nivel de madurez digital y se clasificó entre los cinco primeros de los 17 países de la Organización para la Cooperación y el Desarrollo Económicos (OCDE). Poseemos también sistemas sanitarios digitales altamente avanzados según el Índice de Salud Digital 2019 de la Fundación Bertelsmann.

El Big Data y la IA permiten anticipar con más precisión el comportamiento del cáncer

28-04-2025

La jefa del Laboratorio de Investigación Traslacional de la Fundación MD Anderson Cancer Center Madrid España, la doctora Gema Moreno-Bueno, ha afirmado que el Big Data y la Inteligencia Artificial (IA) permiten anticipar con una mayor precisión el comportamiento del cáncer.

Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts

21-04-2025

Establishing an accurate prognosis remains challenging in older patients with cancer because of the population's heterogeneity and the current predictive models' reduced ability to capture the complex interactions between oncologic and geriatric predictors. We aim to develop and externally validate a new predictive score (the Geriatric Cancer Scoring System [GCSS]) to refine individualized prognosis for older patients with cancer during the first year after a geriatric assessment (GA).

Diagnostic performance of AI-assisted endoscopy diagnosis of digestive system tumors: an umbrella review

07-04-2025

The diagnostic performance of artificial intelligence (AI)-assisted endoscopy for digestive tumors remains controversial. The objective of this umbrella review was to summarize the comprehensive evidence for the AI-assisted endoscopic diagnosis of digestive system tumors. We grouped the evidence according to the location of each digestive system tumor and performed separate subgroup analyses on the basis of the method of data collection and form of the data. We also compared the diagnostic performance of AI with that of experts and nonexperts. For early digestive system cancer and precancerous lesions, AI showed a high diagnostic performance in capsule endoscopy and esophageal squamous cell carcinoma. Additionally, AI-assisted endoscopic ultrasonography (EUS) had good diagnostic accuracy for pancreatic cancer. In the subgroup analysis, AI had a better diagnostic performance than experts for most digestive system tumors. However, the diagnostic performance of AI using video data requires improvement.

Multi-center study: ultrasound-based deep learning features for predicting Ki-67 expression in breast cancer

31-03-2025

Applying deep learning algorithms to mine ultrasound features of breast cancer and construct a machine learning model that accurately predicts Ki-67 expression level. This multi-center retrospective study analyzed clinical and ultrasound data from 929 breast cancer patients. We integrated deep features from the tumor and peritumoral areas to build a fusion model for predicting Ki-67 expression. The model underwent performance validation on both internal and external test datasets. Its accuracy as well as clinical usefulness were evaluated by diverse statistical metrics.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Based Insights

24-03-2025

The integration of artificial intelligence (AI)–powered clinical tools is poised to transform oncology practice, and Scout, a customized large-language model (LLM), AI-powered and expert-trained search tool developed by OncLive®, could provide a streamlined method to aid in treatment decision-making and identifying clinical trial opportunities for patients with cancer, according to Joshua Feinberg, MD.

Machine learning reveals glycolytic key gene in gastric cancer prognosis

17-03-2025

Glycolysis is recognized as a central metabolic pathway in the neoplastic evolution of gastric cancer, exerting profound effects on the tumor microenvironment and the neoplastic growth trajectory. However, the identification of key glycolytic genes that significantly affect gastric cancer prognosis remains underexplored. In this work, five machine-learning algorithms were used to elucidate the intimate association between the glycolysis-associated gene phosphofructokinase fructose-bisphosphate 3 (PFKFB3) and the prognosis of gastric cancer patients. Validation across multiple independent datasets confirmed the prognostic significance of PFKFB3. Further, we delved into the functional implications of PFKFB3 in modulating immune responses and biological processes within gastric cancer patients, as well as its broader relevance across multiple cancer types. Results underscore the potential of PFKFB3 as a prognostic biomarker and therapeutic target in gastric cancer.

Total pages: 18
Suggestions
Diseño y Desarrollo web Im3diA comunicación

Bienvenida/o a la información básica sobre las cookies de la página web responsabilidad de la entidad: Grupo Arán de Comunicación S.L..

Una cookie o galleta informática es un pequeño archivo de información que se guarda en tu ordenador, “smartphone” o tableta cada vez que visitas nuestra página web. Algunas cookies son nuestras y otras pertenecen a empresas externas que prestan servicios para nuestra página web.

Las cookies pueden ser de varios tipos: las cookies técnicas son necesarias para que nuestra página web pueda funcionar, no necesitan de tu autorización y son las únicas que tenemos activadas por defecto.

El resto de cookies sirven para mejorar nuestra página, para personalizarla en base a tus preferencias, o para poder mostrarte publicidad ajustada a tus búsquedas, gustos e intereses personales. Puedes aceptar todas estas cookies pulsando el botón ACEPTA TODO o configurarlas o rechazar su uso clicando en el apartado CONFIGURACIÓN DE COOKIES.

Si quires más información, consulta la “POLITICA COOKIES” de nuestra página web.

COOKIES_ACEPTAR COOKIES_RECHAZAR Configurar Preferencias